Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

Email this article to a friend

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

Princy N Kumar* email, Patricia Salvato* email, Anthony LaMarca* email, Edwin DeJesus* email, Parul Patel* email, Daniel McClernon* email, Allison Florance* email and Mark S Shaefer* email

AIDS Research and Therapy 2009, 6:3doi:10.1186/1742-6405-6-3

Your name*
Your email address*
Recipient's email address*
(multiple email addresses should be separated with commas)
Email format
Please type your message into the box below:
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.